Skip to main content

Drug Interactions between Erex and phentolamine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

phentolamine yohimbine

Applies to: phentolamine and Erex (yohimbine)

Consumer information for this interaction is not currently available.

MONITOR: Concomitant use of multiple vasodilator drugs for the treatment of erectile dysfunction (ED) may increase the risk of additive adverse effects, including hypotension, dizziness, syncope, prolonged erection, or priapism. However, available data are conflicting. For example, approximately 4.9% and 7.1% of people in selected studies using single ingredient intracavernosal injections (ICIs) of papaverine reported experiencing painful/prolonged erections and priapism, respectively. Conversely, selected studies of people using ICIs containing papaverine and phentolamine reported an increase in the average rate of prolonged/painful erections to approximately 8.9%, but a reduction in the average rate of priapism to approximately 5.5%. Additionally, 1 case series reported an increase in dizziness and syncope when patients used both oral agents and ICIs to treat ED. Clinical data are not available for all possible combinations. The route of administration and amount of medication absorbed systemically may affect the clinical significance and severity of this interaction.

MANAGEMENT: Most clinical guidelines advise caution and closer clinical monitoring for patients on erectile dysfunction (ED) regimens that include multiple vasodilative agents due to the potential for additive adverse effects. Some drug manufacturers recommend avoiding combinations due to the potential risks and a lack of established data on safety. However, some of these medications are available as combinations (either commercially or via compounding) and some ED guidelines indicate that combination therapy may be appropriate in certain situations. Healthcare providers should refer to the product labeling and appropriate treatment guidelines for the most up to date information and recommendations; as well as, counsel patients on potential adverse effects and what to do should they occur.

References

  1. "Product Information. Papaverine Hydrochloride (papaverine)." Oryza Pharmaceuticals Inc (2021):
  2. "Product Information. Invicorp (aviptadil-fentolamin)." Evolan Pharma AB (2023):
  3. "Product Information. Caverject (alprostadil)." Pfizer U.S. Pharmaceuticals Group (2023):
  4. "Product Information. Caverject (alprostadil)." Pfizer Ltd (2021):
  5. "Product Information. Caverject Impulse (alprostadil)." Pfizer Australia Pty Ltd pfpcaviv10519 (2019):
  6. "Product Information. Muse (alprostadil)." Meda Pharmaceuticals (2018):
  7. "Product Information. Muse (alprostadil)." Viatris UK Healthcare Ltd (2018):
  8. Dhir RR, Lin HC, Canfield SE, Wang R "Combination therapy for erectile dysfunction: an update review." Asian J Androl 13 (2011): 382-90
  9. Al-Adl AM, Abdel-Wahab O, El-Karamany T, Aal AA "Combined intracavernous vasoactive drugs and sildenafil citrate in treatment of severe erectile dysfunction not responding to on-demand monotherapy." Arab J Urol 9 (2011): 153-8
  10. Karakus S, Burnett AL "The medical and surgical treatment of erectile dysfunction: a review and update. https://www.canjurol.com/abstract.php?ArticleID=&version=1.0&PMID=32876000" (2024):
  11. Burnett AL, Nehra A, Breau RH, et al. "Erectile Dysfunction: AUA Guideline." J Urol 200 (2018): 633-41
  12. Hackett G, Kirby M, Wylie K, et al. "British society for sexual medicine guidelines on the management of erectile dysfunction in men - 2017." J Sex Med 15 (2018): 430-57
  13. Lowy M, Ramanathan V "Erectile dysfunction: causes, assessment and management options. https://australianprescriber.tg.org.au/articles/erectile-dysfunction-causes-assessment-and-management-options.html" (2024):
  14. Domes T, Najafabadi BT, Roberts M, et al. "Canadian urological association guideline: erectile dysfunction." Can Urol Assoc J 10 (2021): 310-22
View all 14 references

Drug and food interactions

Moderate

phentolamine food

Applies to: phentolamine

Phentolamine and ethanol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer